• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 4 filed by Chief Commercial Officer Evans Terry L

    4/3/25 7:14:38 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FENC alert in real time by email
    SEC FORM 4/A SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Evans Terry L

    (Last) (First) (Middle)
    C/O FENNEC PHARMACEUTICALS, INC.
    PO BOX 13628, 68 TW ALEXANDER DRIVE

    (Street)
    RESEARCH TRIANGLE PARK NC 27709

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    FENNEC PHARMACEUTICALS INC. [ FENC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Commercial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    03/28/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    04/03/2025
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Share Unit(1) $0 03/28/2025 A 10,000 03/28/2026(2) 03/28/2035 Common Shares 10,000 $0 160,000 D
    Explanation of Responses:
    1. On March 28, 2025,Terry Evans was awarded restricted share units to acquire 10,000 shares of the issuer's common shares pursuant to the issuer's 2020 Equity Incentive Plan.
    2. One-third of the shares subject to this award shall be released from restriction as of March 28, 2026 (the "Vesting Commencement Date"). One twenty-fourth of the shares subject to this award may be released from restriction as of the last day of each month following the Vesting Commencement Date. As of February 29, 2028 and thereafter, 100% of the total number of shares subject to this award shall be released from restriction.
    /s/ Terry Evans 04/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $FENC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FENC

    DatePrice TargetRatingAnalyst
    11/22/2022$9.00 → $12.00Neutral → Overweight
    Cantor Fitzgerald
    9/7/2022$11.00Overweight
    CapitalOne
    8/8/2022$14.00Buy
    Craig Hallum
    More analyst ratings

    $FENC
    Leadership Updates

    Live Leadership Updates

    See more
    • Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

      ~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced the appointment of Mr. Jeff Hackman as its Chief Executive Officer (CEO) and a member of the Board of Directors, effective on or about August 16, 2024. Jeff will guide Fennec's strategic direction for operational success in the expansion of PEDMARK® use in c

      8/5/24 6:26:00 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      ~ Achieved First Quarter 2025 Total Net Revenues of $8.8 Million, Up 18% Year Over Year ~ ~ Positive Momentum from Company's Refined, Targeted Sales Strategy and Enhanced Patient Support Services ~ ~ PEDMARQSI Now Commercially Available in Germany and the United Kingdom ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today reported its financial results for the first quarter ended March 31, 2025 and provided a business update. "In the first quarter, we sharpened our strategic focus and achieved sustainable gro

      5/13/25 6:03:00 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

      RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date:Tuesday, May 13, 2025Time:8:30 a.m. ETWebcast Link:https://edge.media-server.com/mmc/p/nb5vbq6oParticipant Link:https://register-conf.media-server.com/register/BIbc2eaa3f157d4c6891b71246a83bdb02 To access the li

      5/8/25 4:17:00 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

      ~ Achieved Full-Year PEDMARK® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK® Q4 2024 Net Product Sales of $7.9 Million ~ ~ Delivered Q4 2024 EBITDA Loss of $0.6 Million and Company Has $26.6 Million in Cash, Cash Equivalents and Short-Term Investments ~ ~ Completed Early Repayment of $13 Million of the Company's Convertible Debt Facility ~ ~ Continued Momentum in the Adolescent and Young Adult (AYA) Segment and Academic Setting Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ PEDMARQSI® Now Commercially Available to Patients and Healthcare Providers in the United Kingdom and Germany ~ ~ Japan Clini

      3/10/25 6:03:00 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Andrade Robert bought 12,500 shares, increasing direct ownership by 14% to 104,271 units (SEC Form 4)

      4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

      4/3/24 5:00:11 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raykov Rosty bought 29,167 shares, increasing direct ownership by 10% to 316,638 units (SEC Form 4)

      4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

      4/3/24 4:55:10 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Fennec Pharmaceuticals upgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald upgraded Fennec Pharmaceuticals from Neutral to Overweight and set a new price target of $12.00 from $9.00 previously

      11/22/22 9:21:25 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CapitalOne initiated coverage on Fennec Pharmaceuticals with a new price target

      CapitalOne initiated coverage of Fennec Pharmaceuticals with a rating of Overweight and set a new price target of $11.00

      9/7/22 8:58:27 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Craig Hallum resumed coverage on Fennec Pharmaceuticals with a new price target

      Craig Hallum resumed coverage of Fennec Pharmaceuticals with a rating of Buy and set a new price target of $14.00

      8/8/22 8:53:55 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Raykov Rosty sold $63,100 worth of shares (10,000 units at $6.31), decreasing direct ownership by 16% to 53,587 units (SEC Form 4)

      4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

      5/5/25 6:23:15 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF FINANCIAL OFFICER Andrade Robert was granted 1,042 shares, increasing direct ownership by 0.79% to 133,633 units (SEC Form 4)

      4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

      5/1/25 6:03:46 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Raykov Rosty was granted 2,431 shares, increasing direct ownership by 4% to 63,587 units (SEC Form 4)

      4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

      5/1/25 6:03:04 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Fennec Pharmaceuticals Inc.

      SC 13G/A - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)

      11/12/24 7:38:18 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Fennec Pharmaceuticals Inc.

      SC 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)

      6/27/24 4:43:33 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Fennec Pharmaceuticals Inc.

      SC 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)

      2/14/24 10:47:17 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Fennec Pharmaceuticals Inc.

      DEF 14A - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)

      4/25/25 4:25:31 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Fennec Pharmaceuticals Inc.

      10-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)

      3/26/25 4:34:57 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fennec Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)

      3/10/25 4:46:12 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    Financials

    Live finance-specific insights

    See more
    • Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      ~ Achieved First Quarter 2025 Total Net Revenues of $8.8 Million, Up 18% Year Over Year ~ ~ Positive Momentum from Company's Refined, Targeted Sales Strategy and Enhanced Patient Support Services ~ ~ PEDMARQSI Now Commercially Available in Germany and the United Kingdom ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today reported its financial results for the first quarter ended March 31, 2025 and provided a business update. "In the first quarter, we sharpened our strategic focus and achieved sustainable gro

      5/13/25 6:03:00 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

      RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date:Tuesday, May 13, 2025Time:8:30 a.m. ETWebcast Link:https://edge.media-server.com/mmc/p/nb5vbq6oParticipant Link:https://register-conf.media-server.com/register/BIbc2eaa3f157d4c6891b71246a83bdb02 To access the li

      5/8/25 4:17:00 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

      ~ Achieved Full-Year PEDMARK® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK® Q4 2024 Net Product Sales of $7.9 Million ~ ~ Delivered Q4 2024 EBITDA Loss of $0.6 Million and Company Has $26.6 Million in Cash, Cash Equivalents and Short-Term Investments ~ ~ Completed Early Repayment of $13 Million of the Company's Convertible Debt Facility ~ ~ Continued Momentum in the Adolescent and Young Adult (AYA) Segment and Academic Setting Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ PEDMARQSI® Now Commercially Available to Patients and Healthcare Providers in the United Kingdom and Germany ~ ~ Japan Clini

      3/10/25 6:03:00 AM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FENC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for PEDMARK issued to FENNEC PHARMACEUTICALS INC

      Submission status for FENNEC PHARMACEUTICALS INC's drug PEDMARK (ORIG-1) with active ingredient SODIUM THIOSULFATE has changed to 'Approval' on 09/20/2022. Application Category: NDA, Application Number: 212937, Application Classification: Type 5 - New Formulation or New Manufacturer

      9/20/22 3:54:04 PM ET
      $FENC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care